RecruitingPhase 1Phase 2NCT07375758

A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.

A Phase I/II, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy

Sponsor

Beijing Mabworks Biotech Co., Ltd.

Enrollment

130 participants

Start Date

Feb 5, 2026

Study Type

INTERVENTIONAL

Conditions

Immunoglobulin A Nephropathy

Summary

This is a Phase I/II study designed to evaluate the safety, tolerability, PK and PD of subcutaneous MIL116, an anti-APRIL monoclonal antibody, in healthy participants and patients with IgA Nephropathy.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called MIL116 and a drug called Matching Placebo for people with immunoglobulin a nephropathy. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.